Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2580 | Anti-C1q | Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD. | Human IgG1 |
| A2325 | Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) | Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD. | Human IgG1 |
| A2581 | Icatolimab (Anti-BTLA / CD272) | Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralises the interaction between BTLA and HVEM (Herpesvirus entry mediator). MW: 145.5 KD. | Human IgG4SP |
| A2326 | Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) | Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanised monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW: 145.5 KD. | Human IgG1 |
| A2582 | Onvatilimab (Anti-B7-H5 / VISTA) | Onvatilimab (Anti-B7-H5 / VISTA) is a human IgG1κ monoclonal antibody that targets and binds to VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). It has an anti-tumour activity. MW: 150 KD. | Human IgG1 |
| A2327 | Ragifilimab (Anti-TNFRSF18 / GITR / CD357) | Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumour necrosis factor receptor (tumour necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanised monoclonal antibody with potential immune checkpoint modulating activity. MW: 145.5 KD. | Human IgG1 |
| A2583 | Prezalumab (Anti-B7-H2 / ICOSL / CD275) | Prezalumab (Anti-B7-H2 / ICOSL / CD275) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF. It demonstrates studies for systemic lupus erythematosus arthritis. It is used in the research of Sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE). MW: 145.5 KD. | Human IgG2SA |
| A2329 | Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) | Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD. | Human IgG1 |
| A2330 | lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) | Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW: 145.5 KD. | Human IgG1 |
| A2331 | Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) | Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces Apoptosis via caspase activation. MW: 144.96 KD. | Human IgG1 |
| A3174 | Mosunetuzumab (Anti-CD20 & CD3e) | Mosunetuzumab is a bispecific T-cell-engaging monoclonal antibody that targets CD20 and CD3e, effectively redirecting T cells to eliminate CD20+ malignant B cells. It demonstrates promising efficacy in treating relapsed or refractory follicular lymphoma. MW: 146.72 KD. | human IGg1 |
| A2332 | Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) | Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential anti-tumour activities. MW: 145.5 KD. | Human IgG2SA |
| A2588 | Aducanumab (Anti-Amyloid Beta) | Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research. MW: 145.5 KD. | Human IgG1 |
| A2333 | Tomaralimab (Anti-TLR2 / CD282) | Tomaralimab (Anti-TLR2 / CD282) is a humanised immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2) with potential anti-inflammatory and antineoplastic activities. It has the potential for research on Myelodysplastic Syndromes (MDS). MW : 145.5 KD. | Human IgG4SP |
| A2589 | Birtamimab (Anti-Amyloid Alpha) | Birtamimab (Anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively targets and clears the amyloid. It can be used for treatment to remove amyloid from the vital organs, and research of light chain amyloidosis. MW: 145.5 KD. | Human IgG1 |
| A2334 | Tisotumab (Anti-Tissue factor / CD142) | Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumours. MW : 145.5 KD. | Human IgG1 |
| A2590 | Murlentamab (Anti-AMHR2) | Murlentamab (Anti-AMHR2) is a humanised anti-AMHRII antibody targeting AMHRII. It suppresses tumour growth, stimulates the anti-tumour adaptive immune response through naive macrophage orientation and TAM reprogrammation, in ovarian tumour cells. MW :145.5 KD. | Human IgG1 |
| A2591 | Cinpanemab (Anti-Alpha-synuclein) | Cinpanemab(Anti-Alpha-synuclein) is a human-derived monoclonal antibody that targets and binds to -synuclein. It can be used for the research of Parkinson's disease. MW : 146.98 KD. | Human IgG1 |
| A2336 | Fresolimumab (Anti-TGFb1) | Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD. | Human IgG4SP |
| A2592 | Praluzatamab (Anti-ALCAM / CD166) | Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesise Praluzatamab ravtansine (antibody-drug conjugates) which is used for research of cancers. MW : 150 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.